The chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and more branded products are expected to lose market exclusivity during the next few years. Researcher predicts that the major global barriers that will play a crucial role in narrowing the global growth of the CHF market over the forecast period include the sparsely populated CHF pipeline and an increasing number of generic competitors in a market that is already heavily laden with generic drugs. However, the market entry of entry of Novartis’ LCZ-696, the first novel, branded CHF drug to enter the market in five years, will noticeably enhance the overall market size during the forecast period. LCZ-696 is currently being evaluated in a trial for patients with heart failure with reduced ejection fraction (HF-REF), but if clinical trial data continue to demonstrate the drug’s efficacy in patients with heart failure with preserved ejection fraction (HF-PEF), and it gains approval for use in this population, it will be the first drug to show efficacy in this largely underserved patient population. In addition, increased use of MRAs over the forecast period in all seven major markets (7MM) will contribute to the increase in the global CHF market size.

1. PharmaPoint: Chronic Heart Failure – Global Drug Forecast
and Market Analysis to 2022
by
GlobalData
Explore all reports for “Cardiovascular Disease Drugs ” market
@
http://www.rnrmarketresearch.com/reports/lifesciences/pharmaceuticals/diseases-treatment/cardiovascular-diseasedrugs .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

2. PharmaPoint: Chronic Heart Failure – Global
Drug Forecast and Market Analysis to 2022
The chronic heart failure (CHF) market is a mature market that has been slowly
overtaken by generic drugs, and more branded products are expected to lose
market exclusivity during the next few years. Researcher predicts that the major
global barriers that will play a crucial role in narrowing the global growth of the
CHF market over the forecast period include the sparsely populated CHF pipeline
and an increasing number of generic competitors in a market that is already
heavily laden with generic drugs. However, the market entry of entry of Novartis’
LCZ-696, the first novel, branded CHF drug to enter the market in five years, will
noticeably enhance the overall market size during the forecast period. LCZ-696 is
currently being evaluated in a trial for patients with heart failure with reduced
ejection fraction (HF-REF), but if clinical trial data continue to demonstrate the
drug’s efficacy in patients with heart failure with preserved ejection fraction (HFPEF), and it gains approval for use in this population, it will be the first drug to
show efficacy in this largely underserved patient population. In addition,
increased use of MRAs over the forecast period in all seven major markets
(7MM) will contribute to the increase in the global CHF market size.
Request sample copy of this report @
http://www.rnrmarketresearch.com/contacts/request-sample?rname=150336 .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

3. PharmaPoint: Chronic Heart Failure – Global
Drug Forecast and Market Analysis to 2022
Key Questions Answered
•Although the CHF market has numerous well-established therapies, it is
marked by the presence of a number of unmet needs in current treatments.
What are the main unmet needs in this market? Will the drugs under
development fulfil the unmet needs of the CHF market?
•The late-stage CHF developmental pipeline is sparsely populated, however, the
early stage pipeline is more active and consists of novel pharmacological as well
as non-pharmacological therapeutic approaches. Will the late-stage drugs make
a significant impact on the CHF market? What are the earlier-stage novel,
approaches that drug developers are pursuing?
•Although the incidence of CHF in the US has been relatively constant during
the last decade, its prevalence has been gradually increasing. How will
epidemiological changes impact the growth of the future market?
Complete report available @
http://www.rnrmarketresearch.com/pharmapoint-chronic-heart-failure-globaldrug-forecast-and-market-analysis-to-2022-market-report.html .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

4. PharmaPoint: Chronic Heart Failure – Global
Drug Forecast and Market Analysis to 2022
Scope
•Overview of CHF, including epidemiology, etiology, symptoms, diagnosis, pathology
and treatment guidelines.
•Annualized CHF therapeutics market revenue, annual cost of therapy and treatment
usage pattern data from 2011-2012 and forecast for ten years to 2022.
•Key topics covered include strategic competitor assessment, market
characterization, unmet needs, clinical trial mapping and implications for the CHF
therapeutics market.
•Pipeline analysis: comprehensive data split across different phases, emerging novel
trends under development, including both pharmacological and nonpharmacological therapeutic approaches.
•Analysis of the current and future market competition in the global CHF
therapeutics market. Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide qualitative analysis of
its implications.
Request sample copy of this report @
http://www.rnrmarketresearch.com/contacts/request-sample?rname=150336 .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

5. PharmaPoint: Chronic Heart Failure – Global
Drug Forecast and Market Analysis to 2022
Reasons to buy
•Develop and design your in-licensing and out-licensing strategies through a
review of pipeline products and technologies, and by identifying the companies
with the most robust pipeline.
•Additionally a list of acquisition targets included in the pipeline product
company list.
•Develop business strategies by understanding the trends shaping and driving
the global CHF therapeutics market.
•Drive revenues by understanding the key trends, innovative products and
technologies, market segments, and companies likely to impact the global CHF
therapeutics market in future.
•Formulate effective sales and marketing strategies by understanding the
competitive landscape and by analyzing the performance of various
competitors.
•Identify emerging players with potentially strong product portfolios and create
effective counter-strategies to gain a competitive advantage.
Request sample copy of this report @
http://www.rnrmarketresearch.com/contacts/request-sample?rname=150336 .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

6. PharmaPoint: Chronic Heart Failure – Global
Drug Forecast and Market Analysis to 2022
For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com /
+18883915441
RnR Market Research
RnRMarketResearch.com, an online repository of market research reports, offers in-depth
analysis of over 5000 market segments. RnR Market Research library has syndicated reports by
leading market research publishers across the globe.
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441